EVALUATION OF THE EFFICIENCY OF FOUR PREVENTION STRATEGIES IN ALZHEIMER'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) STUDY
Author(s)
Costa N1, Mounié M1, Pagès A2, Guyonnet S3, Carrié I3, Coley N4, Cantet C5, Rapp T6, Derumeaux-Burel H7, Andrieu S3, Vellas B1, Molinier L1
1Toulouse University Hospital, Toulouse, France, 2University Hospital of Toulouse, Toulouse, 31, France, 3University Hospital of Toulouse, Toulouse, France, 4National Institute For Health and Medical Research (INSERM), Toulouse, France, 5University hospital of toulouse, Toulouse, France, 6University Paris Descartes, Paris, France, 7Toulouse University hospital, toulouse, France
OBJECTIVES According to the WHO, Alzheimer Disease represents approximately 50 million of demented people with a societal cost estimated to US$ 818 billion worldwide. Nevertheless, no curative treatment is available putting forward the need to develop prevention strategies. Current evidences suggest that nutrition, physical exercise, cognitive activity and social stimulation may improve cognitive health. We aim to assess the efficiency of an isolated supplementation with omega-3 fatty acid (OMG3), an isolated multidomain intervention (IM) (nutritional counseling, physical exercise, cognitive stimulation) or both interventions together (OMG3+IM) on the change of cognitive functions in comparison with a placebo. METHODS We have used data from the Multidomain Alzheimer Preventive Trial (MAPT) study, which focus on change in memory function, through a composite score combining four cognitive tests, after 3 years of follow-up of frail subjects aged 70 years and older in France. Effectiveness used was the per-10 percent of no aggravation in memory function. Health insurance perspective was taken into account and direct costs were included in the analysis. Incremental Cost Effectiveness Ratio (ICER) and its 95% confident ellipse were implemented for each strategy in comparison with placebo. RESULTS Analyses were carried out on 1525 patients. Per 10 percent of no aggravation at 3 years were respectively 2.92, 2.47, 3.18 and 2.99 for placebo, OMG3, IM and OMG3+IM strategy. Mean costs per patients at 3 years were respectively €5,508; €6,404; €6,164; €7,299 for placebo, OMG3, IM and OMG3 + IM strategies. The OMG3 strategy was dominated while ICER for IM and OMG3+IM were estimated to €2,538 and €24,341 per 10% of no aggravation respectively compared to the placebo. Conclusions do not change according to deterministic and probabilistic sensitive analyses. CONCLUSIONS According to ICERs and confident ellipses the IM strategy were assessed as the most efficient intervention.
Conference/Value in Health Info
2020-05, ISPOR 2020, Orlando, FL, USA
Value in Health, Volume 23, Issue 5, S1 (May 2020)
Code
PND44
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Geriatrics, Neurological Disorders, Nutrition
Explore Related HEOR by Topic